Synonym
TRECETILIDE FUMARATE; U-108342E
IUPAC/Chemical Name
(S)-N-(4-(4-(ethyl(6-fluoro-6-methylheptyl)amino)-1-hydroxybutyl)phenyl)methanesulfonamide hemifumarate
InChi Key
ODFOUAATRQAOLG-MMSVOLSESA-N
InChi Code
InChI=1S/2C21H37FN2O3S.C4H4O4/c2*1-5-24(16-8-6-7-15-21(2,3)22)17-9-10-20(25)18-11-13-19(14-12-18)23-28(4,26)27;5-3(6)1-2-4(7)8/h2*11-14,20,23,25H,5-10,15-17H2,1-4H3;1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*20-;/m00./s1
SMILES Code
OC(=O)\C=C\C(O)=O.CCN(CCCCCC(C)(C)F)CCC[C@H](O)C1=CC=C(NS(C)(=O)=O)C=C1.CCN(CCCCCC(C)(C)F)CCC[C@H](O)C2=CC=C(NS(C)(=O)=O)C=C2
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
949.26
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Buist SC, Hsu CY, Walters RR. Sensitive determination of a new antiarrhythmic agent, trecetilide, in plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr A. 1998 Dec 18;828(1-2):259-65. PubMed PMID: 9916311.
2: Doggrell SA, Hancox JC. Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. Expert Opin Investig Drugs. 2005 May;14(5):655-69. Review. PubMed PMID: 15926871.
3: Camm AJ, Yap YG. What should we expect from the next generation of antiarrhythmic drugs? J Cardiovasc Electrophysiol. 1999 Feb;10(2):307-17. Review. PubMed PMID: 10090237.
4: Sager PT. New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol. 2000 Jan;15(1):41-53. Review. PubMed PMID: 10666660.
5: Lee K, Park JY, Ryu PD, Kwon LS, Kim HY. IKr channel blockers: novel antiarrhythmic agents. Curr Med Chem Cardiovasc Hematol Agents. 2003 Oct;1(3):203-23. Review. PubMed PMID: 15326913.
6: Humphrey SJ, Turman CN, Curry JT, Wheeler GJ. Cardiovascular and electrocardiographic effects of the dopamine receptor agonists ropinirole, apomorphine, and PNU-142774E in conscious beagle dogs. J Cardiovasc Pharmacol. 2006 Mar;47(3):337-47. PubMed PMID: 16633074.
7: Hester JB, Gibson JK, Buchanan LV, Cimini MG, Clark MA, Emmert DE, Glavanovich MA, Imbordino RJ, LeMay RJ, McMillan MW, Perricone SC, Squires DM, Walters RR. Progress toward the development of a safe and effective agent for treating reentrant cardiac arrhythmias: synthesis and evaluation of ibutilide analogues with enhanced metabolic stability and diminished proarrhythmic potential. J Med Chem. 2001 Mar 29;44(7):1099-115. PubMed PMID: 11297456.
8: Gupta AK, Maheshwari A, Thakur RK, Lokhandwala YY. Newer antiarrhythmic drugs. Indian Heart J. 2001 May-Jun;53(3):354-60. Review. PubMed PMID: 11516042.
